Quick Summary:
The global Respiratory Syncytial Virus (RSV) Therapeutics market is on a dramatic trajectory, projected to catapult from a valuation of $1 Billion in 2022 to an astonishing $7.8 Billion by 2030. Align your business with this rapid acceleration by acknowledging the detailed insights provided by our thoroughly researched RSV Therapeutics market report.
This report offers a comprehensive analysis of important segments such as Prophylaxis, showing an impressive CAGR prediction of 28.5%, and Treatment, reflecting a surge to a revised 34.8% CAGR in the upcoming eight years. Featuring notable geographies, it provides an unparalleled understanding of emerging markets like China, set to trail a 28% CAGR over the analysis period. The stewardship and strategic planning facilitated by this report are indispensable in navigating this dynamic sector. With in-depth competitive analysis featuring 41 industry leaders, the report serves as a navigational compass in this rapidly evolving market.
Global Respiratory Syncytial Virus (RSV) Therapeutics Market to Reach $7.8 Billion by 2030
The global market for Respiratory Syncytial Virus (RSV) Therapeutics estimated at US$1 Billion in the year 2022, is projected to reach a revised size of US$7.8 Billion by 2030, growing at a CAGR of 29.2% over the analysis period 2022-2030. Prophylaxis, one of the segments analyzed in the report, is projected to record 28.5% CAGR and reach US$6.8 Billion by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Treatment segment is readjusted to a revised 34.8% CAGR for the next 8-year period.
The U.S. Market is Estimated at $304 Million, While China is Forecast to Grow at 28% CAGR
The Respiratory Syncytial Virus (RSV) Therapeutics market in the U.S. is estimated at US$304 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$1.3 Billion by the year 2030 trailing a CAGR of 28% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 26.3% and 25% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 20.4% CAGR.Select Competitors (Total 41 Featured) -
- AbbVie, Inc.
- AstraZeneca PLC
- Bausch Health Companies Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- ReViral Ltd.
- Teva Pharmaceutical Industries Ltd.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its `bumpy` reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and the publisher's Research Platform
- Complimentary updates for one year
What is the estimated value of the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics?
What is the growth rate of the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics?
What is the forecasted size of the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics?
Who are the key companies in the Global Market for Respiratory Syncytial Virus (RSV) Therapeutics?
| Report Attribute | Details |
|---|---|
| No. of Pages | 194 |
| Published | September 2023 |
| Forecast Period | 2022 - 2030 |
| Estimated Market Value ( USD | $ 1 Billion |
| Forecasted Market Value ( USD | $ 7.8 Billion |
| Compound Annual Growth Rate | 29.3% |
| Regions Covered | Global |
Table of Contents
Companies Mentioned
A selection of companies mentioned in this report includes:
- AbbVie, Inc.
- AstraZeneca PLC
- Bausch Health Companies Inc.
- F. Hoffmann-La Roche AG
- Gilead Sciences, Inc.
- GlaxoSmithKline PLC
- Merck & Co., Inc.
- ReViral Ltd.
- Teva Pharmaceutical Industries Ltd.
